All‐cause mortality · adults in sinus rhythm after cardioversion of atrial fibrillation
Dofetilide showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults in sinus rhythm after cardioversion of atrial fibrillation
Dofetilide showed no clear difference in withdrawals due to adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review
Proarrhythmia · adults in sinus rhythm after cardioversion of atrial fibrillation
Dofetilide probably leads to higher proarrhythmia compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Stroke · adults in sinus rhythm after cardioversion of atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of atrial fibrillation · adults in sinus rhythm after cardioversion of atrial fibrillation
Dofetilide probably leads to lower recurrence of atrial fibrillation compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Periprocedural complications and other safety outcomes · people with non‐paroxysmal atrial fibrillation
It is very uncertain whether ablation changes periprocedural complications and other safety outcomes compared with antiarrhythmic drug (very low certainty).
1 finding from 1 review
Intervention not reported
Kidney injury (safety outcome) (hospital stay)
The intervention showed no clear difference in kidney injury (safety outcome) (hospital stay) (low certainty).
1 finding from 1 review
Procedural complications · DCM (non‐ischaemic)
1 finding from 1 review
Adverse events (any type) and safety of sealant · patients with myocardial infarction
It is very uncertain whether lidocaine changes safety (AEs; adverse drug reaction): any adverse event compared with pirmenol (very low certainty).
1 finding from 1 review
Freedom from atrial arrhythmia · people with non‐paroxysmal atrial fibrillation
Ablation may leads to higher freedom from atrial arrhythmia compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Participants needing cardioversion · people with non‐paroxysmal atrial fibrillation
Ablation probably leads to lower participants needing cardioversion compared with antiarrhythmic drug (moderate certainty).
1 finding from 1 review
Cardiac hospitalisation Hospitalisations directly related to ablation or antiarrhythmic drugs · people with non‐paroxysmal atrial fibrillation
Ablation may leads to lower cardiac hospitalisation Hospitalisations directly related to… compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Significant bradycardia or need for a pacemaker · people with non‐paroxysmal atrial fibrillation
Ablation showed no clear difference in significant bradycardia or need for a pacemaker compared with antiarrhythmic drug (low certainty).
1 finding from 1 review